Want to see HK:2216 full AI Analyst Report?
2216 Stock Chart & Stats
HK$2.36
HK$0.01(1.61%)
At close: 4:00 PM EST
HK$2.36
HK$0.01(1.61%)
Day’s Range― - ―
52-Week RangeHK$0.53 - HK$3.72
Previous CloseN/A
Volume341.00K
Average Volume (3M)2.03M
Market Cap
HK$322.53M
Enterprise Value-HK$38.70
Total Cash (Recent Filing)HK$69.24M
Total Debt (Recent Filing)HK$16.00K
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding528,737,060
10 Day Avg. Volume1,907,700
30 Day Avg. Volume2,030,864
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)0.99
Price to Sales (P/S)850.01
P/FCF Ratio-14.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$16.96M
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt and positive equity reduce refinancing pressure and give Broncus more flexibility to fund operations, product development, or restructuring. This balance-sheet support is durable, although it cannot offset prolonged operating losses indefinitely.
EU Regulatory ExpansionEU MDR certification expands the addressable market for Broncus’s lung catheter and removes a key commercialization barrier. Broader regulatory coverage can support international sales, diversify revenue sources, and strengthen the company’s competitive position.
Specialized Product CapabilityA specialized catheter targeting advanced lung interventions may support differentiation in a technically demanding medical-device niche. Its use across diagnostic and therapeutic procedures could improve adoption potential as global commercialization develops.
Bears Say
Severe Revenue DeclineA roughly 97% revenue contraction indicates a major loss of commercial traction rather than ordinary volatility. Unless sales recover materially, the smaller revenue base will limit operating leverage, weaken market position, and make sustained investment harder.
Persistent Deep LossesMulti-year operating and net losses, combined with a recent negative gross profit, show that the current model is not covering its cost base. Continued losses can erode equity, constrain product investment, and increase dependence on external capital.
Ongoing Cash BurnPersistent negative operating and free cash flow means Broncus cannot currently self-fund its operations. Even with some latest-year improvement, continued cash consumption may require financing or asset support, creating execution and dilution risks over time.
Broncus Holding Corp. News
2216 FAQ
What was Broncus Holding Corp.’s price range in the past 12 months?
Broncus Holding Corp. lowest stock price was HK$0.53 and its highest was HK$3.72 in the past 12 months.
What is Broncus Holding Corp.’s market cap?
Broncus Holding Corp.’s market cap is HK$322.53M.
When is Broncus Holding Corp.’s upcoming earnings report date?
Broncus Holding Corp.’s upcoming earnings report date is Aug 27, 2026 which is today.
How were Broncus Holding Corp.’s earnings last quarter?
Currently, no data Available
Is Broncus Holding Corp. overvalued?
According to Wall Street analysts Broncus Holding Corp.’s price is currently Overvalued.
Does Broncus Holding Corp. pay dividends?
Broncus Holding Corp. does not currently pay dividends.
What is Broncus Holding Corp.’s EPS estimate?
Broncus Holding Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Broncus Holding Corp. have?
Broncus Holding Corp. has 528,737,060 shares outstanding.
What happened to Broncus Holding Corp.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Broncus Holding Corp.?
Currently, no hedge funds are holding shares in HK:2216
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Broncus Holding Corp. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
Broncus Holding Corp.
Broncus Holding Corporation is a global medical technology company specializing in the development of interventional pulmonology products. Its market reach extends across Mainland China, the European Union, the United States, and other international territories. The company's innovative product lineup includes advanced navigation systems such as LungPoint Virtual Bronchoscopic Navigation, a sophisticated computer-assisted image-based software solution. It also offers LungPoint Plus, a system providing real-time airway guidance crucial for lung biopsies and other medical interventions, and LungPro, a virtual bronchoscopic navigation product that enables three-dimensional real-time guided transbronchial needle aspiration alongside proprietary parenchymal navigation. Beyond navigation, Broncus provides a suite of therapeutic products. These feature InterVapor, a targeted bronchoscopic thermal vapor ablation system designed to treat diseased, hyper-inflated lung segments. Additionally, it offers an RF Generator paired with an RF Ablation Catheter, forming a radiofrequency ablation system specifically developed to target lung cancer. The H-Marker, a pulmonary surgical marker, is another key offering. The company further supplies a range of specialized procedural devices, including the BioStarNeedle, a single-use ultrasound-guided aspiration needle for retrieving tissue samples, and the FleXNeedle, a versatile multipurpose biopsy needle. Complementing these are various bronchoscopic accessories like the Archimedes Sheath, a sterile, single-use flexible tube that serves as a working channel during bronchoscopic procedures. The Archimedes Dilation Balloon, another sterile, single-use flexible tube with a distal balloon, is used to dilate target lung tissue within the bronchial tree after insertion through a bronchoscope or sheath. Finally, the Steerable Sheath provides a steerable adjustment handle and an additional working channel. Broncus Holding Corporation was established in 2012 and maintains its corporate headquarters in Hangzhou, China.
Technical Analysis
MicroPort Scientific
―
Vincent Medical Holdings Limited
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
―
Rainmed Medical Limited
―







